Monday, 8 April 2019

Alnylam, Regeneron to partner for RNAi treatments

Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)